| Annovis Bio is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Co.'s primary compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. For acute indications, Co. is developing ANVS405, focused on protecting the brain after traumatic brain injury and/or stroke. Co. is also developing its compound, ANVS301, to increase cognitive capability in later stages of AD and dementia. We show 4 historical shares outstanding datapoints in our ANVS shares outstanding history coverage, used to compute ANVS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANVS market cap history over the course of time is important for investors
interested in comparing ANVS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANVS versus a peer is one thing; comparing
ANVS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANVS can fluctuate over the course of history.
With this page we aim to empower investors researching ANVS by allowing them to research the ANVS market cap history.